Published in Cancer Res on November 17, 2009
Selective targeting of radiation-resistant tumor-initiating cells. Proc Natl Acad Sci U S A (2010) 1.99
Mitochondria-ros crosstalk in the control of cell death and aging. J Signal Transduct (2011) 1.89
The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget (2010) 1.64
Tumor suppressor functions of FBW7 in cancer development and progression. FEBS Lett (2012) 1.64
Autophagy inhibition for chemosensitization and radiosensitization in cancer: do the preclinical data support this therapeutic strategy? J Pharmacol Exp Ther (2013) 1.24
β-Elemene-induced autophagy protects human gastric cancer cells from undergoing apoptosis. BMC Cancer (2011) 1.21
Autophagy modulation for cancer therapy. Cancer Biol Ther (2011) 1.20
Glycogen synthase kinase 3 inhibition promotes lysosomal biogenesis and autophagic degradation of the amyloid-β precursor protein. Mol Cell Biol (2012) 1.18
Fisetin induces autophagic cell death through suppression of mTOR signaling pathway in prostate cancer cells. Carcinogenesis (2010) 1.17
A mechanism for synergy with combined mTOR and PI3 kinase inhibitors. PLoS One (2011) 1.12
Mammalian target of rapamycin: a central node of complex signaling cascades. Int J Clin Exp Pathol (2011) 1.11
Aberrant regulation of FBW7 in cancer. Oncotarget (2014) 1.08
The two faces of FBW7 in cancer drug resistance. Bioessays (2011) 1.08
Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma. Clin Cancer Res (2011) 1.07
The Akt-inhibitor Erufosine induces apoptotic cell death in prostate cancer cells and increases the short term effects of ionizing radiation. Radiat Oncol (2010) 1.04
The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells. J Clin Endocrinol Metab (2011) 1.04
Survival or death: disequilibrating the oncogenic and tumor suppressive autophagy in cancer. Cell Death Dis (2013) 0.99
Temporal mTOR inhibition protects Fbxw7-deficient mice from radiation-induced tumor development. Aging (Albany NY) (2013) 0.94
Inducing autophagy: a comparative phosphoproteomic study of the cellular response to ammonia and rapamycin. Autophagy (2013) 0.92
Allele-specific deletions in mouse tumors identify Fbxw7 as germline modifier of tumor susceptibility. PLoS One (2012) 0.88
The mTORC2 component rictor contributes to cisplatin resistance in human ovarian cancer cells. PLoS One (2013) 0.86
Perifosine induces protective autophagy and upregulation of ATG5 in human chronic myelogenous leukemia cells in vitro. Acta Pharmacol Sin (2012) 0.86
Recent advances in SCF ubiquitin ligase complex: Clinical implications. Biochim Biophys Acta (2016) 0.85
Understanding the interplay between the proteasome pathway and autophagy in response to dual PI3K/mTOR inhibition in myeloma cells is essential for their effective clinical application. Leukemia (2013) 0.85
Protective autophagy antagonizes oxaliplatin-induced apoptosis in gastric cancer cells. Chin J Cancer (2011) 0.84
Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients. BMC Cancer (2015) 0.84
Upregulation of autophagy-related gene-5 (ATG-5) is associated with chemoresistance in human gastric cancer. PLoS One (2014) 0.84
AEG-1 is a target of perifosine and is over-expressed in gastric dysplasia and cancers. Dig Dis Sci (2013) 0.84
Evaluating the prognostic significance of FBXW7 expression level in human breast cancer by a meta-analysis of transcriptional profiles. J Cancer Sci Ther (2012) 0.84
Essential role of autophagy in fucoxanthin-induced cytotoxicity to human epithelial cervical cancer HeLa cells. Acta Pharmacol Sin (2013) 0.83
Role of autophagy in the host response to microbial infection and potential for therapy. Curr Opin Immunol (2010) 0.82
Perifosine enhances mTORC1-targeted cancer therapy by activation of GSK3β in NSCLC cells. Cancer Biol Ther (2012) 0.82
mTOR pathway activation in multiple myeloma cell lines and primary tumour cells: pomalidomide enhances cytoplasmic-nuclear shuttling of mTOR protein. Oncoscience (2015) 0.81
Regulation of GATA-binding protein 2 levels via ubiquitin-dependent degradation by Fbw7: involvement of cyclin B-cyclin-dependent kinase 1-mediated phosphorylation of THR176 in GATA-binding protein 2. J Biol Chem (2015) 0.81
Assessment of the effect of sphingosine kinase inhibitors on apoptosis,unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics. Oncotarget (2014) 0.81
In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines. Invest New Drugs (2010) 0.81
Ceramide mediates nanovesicle shedding and cell death in response to phosphatidylinositol ether lipid analogs and perifosine. Cell Death Dis (2012) 0.81
Multiple novel alternative splicing forms of FBXW7α have a translational modulatory function and show specific alteration in human cancer. PLoS One (2012) 0.79
Rictor Undergoes Glycogen Synthase Kinase 3 (GSK3)-dependent, FBXW7-mediated Ubiquitination and Proteasomal Degradation. J Biol Chem (2015) 0.79
Inhibition of lysosome degradation on autophagosome formation and responses to GMI, an immunomodulatory protein from Ganoderma microsporum. Br J Pharmacol (2012) 0.79
Murine toxicology and pharmacokinetics evaluation of retinoic acid metabolism blocking agent (RAMBA), VN/12-1. Cancer Chemother Pharmacol (2012) 0.78
Cul4A overexpression associated with Gli1 expression in malignant pleural mesothelioma. J Cell Mol Med (2015) 0.77
In vitro effects of perifosine, bortezomib and lenalidomide against hematopoietic progenitor cells from healthy donors. Invest New Drugs (2011) 0.76
Role of Autophagy and Apoptosis in Non-Small-Cell Lung Cancer. Int J Mol Sci (2017) 0.75
Collaborating Pathways that Functionally Amplify NOTCH1 Signals in T-Cell Acute Lymphoblastic Leukemia. J Hematol Transfus (2013) 0.75
Endogenous transmembrane protein UT2 inhibits pSTAT3 and suppresses hematological malignancy. J Clin Invest (2016) 0.75
CISD2 enhances the chemosensitivity of gastric cancer through the enhancement of 5-FU-induced apoptosis and the inhibition of autophagy by AKT/mTOR pathway. Cancer Med (2017) 0.75
Aldose reductase interacts with AKT1 to augment hepatic AKT/mTOR signaling and promote hepatocarcinogenesis. Oncotarget (2017) 0.75
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 38.99
Autophagy in the pathogenesis of disease. Cell (2008) 34.68
Autophagy fights disease through cellular self-digestion. Nature (2008) 33.83
The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer (2002) 28.11
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med (2007) 24.19
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell (2006) 18.36
mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell (2002) 18.22
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol (2004) 16.83
How to interpret LC3 immunoblotting. Autophagy (2007) 12.30
Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature (2006) 12.13
mTOR and cancer: insights into a complex relationship. Nat Rev Cancer (2006) 11.86
Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov (2005) 11.46
Autophagy in cell death: an innocent convict? J Clin Invest (2005) 10.70
The TOR pathway: a target for cancer therapy. Nat Rev Cancer (2004) 9.02
Potential therapeutic applications of autophagy. Nat Rev Drug Discov (2007) 8.56
FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer (2008) 7.93
Dynamic FoxO transcription factors. J Cell Sci (2007) 6.30
Inactivation of hCDC4 can cause chromosomal instability. Nature (2004) 5.71
The Akt-mTOR tango and its relevance to cancer. Cancer Cell (2005) 5.34
FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science (2008) 3.78
An expanding role for mTOR in cancer. Trends Mol Med (2005) 3.40
Will mTOR inhibitors make it as cancer drugs? Cancer Cell (2003) 3.15
United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling. Biochem Soc Trans (2003) 2.34
Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res (2007) 2.28
Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther (2003) 2.24
Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst (2004) 2.13
Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells. Cancer Res (1997) 1.96
Perifosine: update on a novel Akt inhibitor. Curr Oncol Rep (2009) 1.73
Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res (2005) 1.46
Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells. Oncogene (1999) 1.41
The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway. Mol Cancer Ther (2007) 1.33
Synergistic induction of apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways. Mol Cancer Ther (2006) 1.10
Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C225 by perifosine in PTEN-deficient cancer cells. Oncogene (2006) 1.06
D-21266, a new heterocyclic alkylphospholipid with antitumour activity. Eur J Cancer (1997) 1.06
Perifosine, a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest. Cancer Res (2002) 1.05
In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines. Clin Cancer Res (2004) 1.04
Forkhead box protein O1 negatively regulates skeletal myocyte differentiation through degradation of mammalian target of rapamycin pathway components. Endocrinology (2007) 1.04
Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid. Invest New Drugs (2005) 0.94
Alkyl-lysophospholipids as anticancer agents and enhancers of radiation-induced apoptosis. Int J Radiat Oncol Biol Phys (2001) 0.93
Antibody neutralization and escape by HIV-1. Nature (2003) 21.48
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med (2005) 15.30
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother (2002) 13.91
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med (2007) 8.41
The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov (2011) 7.57
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res (2005) 7.34
Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal (2009) 5.57
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood (2012) 5.11
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol (2006) 4.87
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood (2010) 4.52
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood (2011) 4.00
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood (2007) 3.66
Primary intestinal epithelial cells selectively transfer R5 HIV-1 to CCR5+ cells. Nat Med (2002) 3.04
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst (2005) 2.99
Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism. Mol Cell (2011) 2.61
PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood (2013) 2.59
FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Cancer Cell (2007) 2.56
Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res (2002) 2.50
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol (2008) 2.45
Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res (2005) 2.43
Lung cancer: New biological insights and recent therapeutic advances. CA Cancer J Clin (2011) 2.42
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood (2012) 2.41
Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. Cancer Cell (2012) 2.39
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol (2009) 2.32
Translation of innovative designs into phase I trials. J Clin Oncol (2007) 2.30
Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. J Clin Oncol (2009) 2.15
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk Lymphoma (2012) 2.14
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood (2011) 2.13
Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst (2004) 2.13
Eliminating the complete response penalty from myeloma response assessment. Blood (2008) 2.11
Head and neck cancer chemoprevention gets a shot in the arm. J Clin Oncol (2008) 2.09
A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res (2013) 2.02
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood (2014) 2.01
Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors. Blood (2011) 2.01
Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer Res (2008) 2.01
Perspectives for cancer prevention with natural compounds. J Clin Oncol (2009) 1.99
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol (2013) 1.99
Cancer prevention with natural compounds. Semin Oncol (2010) 1.98
Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Res (2006) 1.94
Therapeutic misconception, misestimation, and optimism in participants enrolled in phase 1 trials. Cancer (2012) 1.94
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol (2009) 1.92
Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biol Blood Marrow Transplant (2013) 1.88
Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells. Clin Cancer Res (2006) 1.85
Salvage second hematopoietic cell transplantation in myeloma. Biol Blood Marrow Transplant (2013) 1.80
Neuronal chemorepellent Slit2 inhibits vascular smooth muscle cell migration by suppressing small GTPase Rac1 activation. Circ Res (2006) 1.79
Dynamic 14-3-3/client protein interactions integrate survival and apoptotic pathways. Semin Cancer Biol (2006) 1.78
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica (2013) 1.76
Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial. J Natl Cancer Inst (2003) 1.75
EVI1 induces myelodysplastic syndrome in mice. J Clin Invest (2004) 1.72
PPARgamma ligands enhance TRAIL-induced apoptosis through DR5 upregulation and c-FLIP downregulation in human lung cancer cells. Cancer Biol Ther (2007) 1.71
New paradigm in dose-finding trials: patient-specific dosing and beyond phase I. Clin Cancer Res (2005) 1.70
HIV binding, penetration, and primary infection in human cervicovaginal tissue. Proc Natl Acad Sci U S A (2005) 1.67
A soma-to-germline transformation in long-lived Caenorhabditis elegans mutants. Nature (2009) 1.63
Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood (2006) 1.63
Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. Cancer Prev Res (Phila) (2009) 1.57
Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. Cancer Prev Res (Phila) (2013) 1.56
Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation. Mol Cell Biol (2007) 1.54
Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597. J Clin Oncol (2013) 1.54
Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients. Cancer Prev Res (Phila) (2011) 1.53
Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol (2010) 1.53
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol (2014) 1.52
Oxidative capacity in failing hearts. Am J Physiol Heart Circ Physiol (2003) 1.51
p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells. J Clin Invest (2010) 1.50
Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol (2002) 1.50
Down-regulation of 14-3-3zeta suppresses anchorage-independent growth of lung cancer cells through anoikis activation. Proc Natl Acad Sci U S A (2007) 1.49
An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk (2012) 1.48
Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer (2004) 1.47
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood (2014) 1.47